NCT05241613终止1 期
A Phase I Study to Evaluate Safety, Tolerability, PK, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Progressed on at Least Two Prior Systemic Therapies
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 28
- 试验地点
- 5
- 主要终点
- Incidence of dose limiting toxicities (DLTs) from AC176 monotherapy
研究概览
简要总结
This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies.
The main goals of this study are to:
- Identify the recommended dose of AC176 that can be given safely to participants
- Evaluate the side effects of AC176
- Evaluate pharmacokinetics of AC176
- Evaluate the effectiveness of AC176
详细描述
AC176-001 is a Phase I, first-in-human, open-label, multi-center dose-escalation study of AC176 given as a single agent. The AC176 is an investigational medicinal product that is a potent orally bioavailable Androgen Receptor (AR) degrader studied for the treatment of Metastatic Castration Resistant Prostate Cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Males who are at least 18 years-of-age at the time of signature of the informed consent form (ICF)
- •Patients with histological, pathological, or cytological confirmed diagnosis of advanced or mCRPC who have had disease progression per Prostate Cancer Working Group 3(PCWG3) guidance following standard treatment, including approved taxane-based chemotherapy, or who are not amenable (intolerability, patient choice) to standard therapies, or for whom no therapy of proven efficacy exists.
- •Advanced or metastatic disease per PCWG3 guidance documented by either:
- •Positive bone scan (2 lesions) or metastatic lesions on computed tomography (CT)/magnetic resonance imaging (MRI) that can be followed for response.
- •Prostate-specific antigen (PSA) values with a starting value of ≥1.0 ng/mL that have increased on 3 occasions obtained a minimum of 1 week apart.
- •Patients must have progressed on at least 2 prior approved systemic therapies (in any setting), with at least 1 being abiraterone, or enzalutamide, or apalutamide or darolutamide
- •Patients who have had surgical or medical castration.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 1
- •Life expectancy ≥3 months after the start of the treatment according to the Investigator's judgment
排除标准
- •Patients who meet any of the following criteria will be excluded from study entry:
- •Treatment with any of the following:
- •More than 2 lines of chemotherapy
- •Any systemic anti-cancer therapy, chemotherapy, biologic, or hormonal agent from a previous treatment regimen or clinical study within 4 weeks prior to the first dose of study drug. Any systemic small molecules from a previous treatment regimen or clinical study within 2 weeks or 5 half-lives (whichever is longer, not to exceed 4 weeks) prior to the first dose of study drug, except ADT for medical castration purpose.
- •Any investigational agents from a previous clinical study within 4 weeks prior to the first dose of study treatment
- •Radiation therapy (including therapeutic radioisotopes) within 4 weeks prior to first dose of study drug. Radiation for palliation within 2 weeks of study drug. Palliative radiation for the alleviation of pain due to bone metastasis will be allowed during the study
- •With the exception of alopecia and ≤ Grade 2 peripheral neuropathy, any unresolved toxicities from prior therapy greater than the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 1 at the time of starting study treatment. Note: subjects with chronic Grade 2 toxicities that are asymptomatic or adequately managed with stable medication may be eligible with Sponsor approval
- •Major surgery (excluding placement of vascular access) within 4 weeks of first dose of study drug.
- •Known symptomatic brain metastases requiring steroids (above physiologic replacement doses)
- •Men who plan to father a child while in the study or within 90 days after the last administration of study treatment
- •Any condition that impairs a patient's ability to swallow whole pills. Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of AC176 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea Grade ≥2, malabsorption syndrome)
- •Any of the following cardiac criteria experienced currently or within the last 6 months:
- •Mean resting corrected QT interval (QTc) >470 msec
- •Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting electrocardiograms (ECGs), e.g., complete left bundle branch block, third-degree heart block
- •Congestive heart failure (New York Heart Association ≥ Grade 2)
- •Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT interval
- •Left ventricular ejection fraction (LVEF) <50% or the lower limit of normal of the institutional standard.
- •As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, uncontrolled diabetes mellitus, active bleeding diatheses, or active infection. Screening for chronic conditions is not required. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.
研究组 & 干预措施
AC176 Dose Escalation as Single Agent
Experimental
Single agent dose escalation of AC176. AC176 will be given orally (PO) on a 28-day cycle.
干预措施: AC176 (Drug)
结局指标
主要结局
Incidence of dose limiting toxicities (DLTs) from AC176 monotherapy
时间窗: 28 days
Number of subjects with DLT
Number of patients with vital signs abnormalities
时间窗: Through study completion, approximately 24 months
Vital signs abnormalities as characterized by type, frequency, severity and timing
Incidence of Electrocardiogram (ECG) abnormalities as a measure of safety and tolerability of AC176
时间窗: Through study completion, approximately 24 months
Electrocardiogram (ECG) abnormalities such as heart rate, QTcF, PR, RR and QRS intervals
Incidence of laboratory abnormalities as a measure of safety and tolerability of AC176
时间窗: Through study completion, approximately 24 months
Laboratory abnormalities as characterized by type, frequency, severity and timing
Adverse events (AEs)/Serious adverse events (SAEs)
时间窗: Through study completion, approximately 24 months
Number of adverse events as characterized by type, frequency, seriousness, and relationship to AC176
次要结局
- Title: Duration of Response (DoR)(Throughout the study, approximately 24 months)
- Objective Response Rate(ORR)(Throughout the study, approximately 24 months)
- Pharmacokinetic Analysis: time to maximum plasma concentration (tmax)(20 weeks)
- Pharmacokinetic Analysis: terminal elimination half life (t1/2)(20 weeks)
- Pharmacokinetic Analysis: area under the concentration-time curve over the dosing interval (AUC(0-tau))(20 weeks)
- Prostate-Specific Antigen (PSA) response rate(Throughout the study, approximately 24 months)
- Time-to-Progression (TTP)(Throughout the study, approximately 24 months)
- Pharmacokinetic Analysis: area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC(0-inf))(20 weeks)
- Pharmacokinetic Analysis: maximum plasma concentration (Cmax)(20 weeks)
研究者
研究点 (5)
Loading locations...
相似试验
终止
1 期
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate CancerMetastatic Castration Resistant Prostate CancerNCT05673109Accutar Biotechnology Inc8
进行中（未招募）
1 期
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast CancerBreast CancerNCT05654532Accutar Biotechnology Inc100
终止
1 期
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast CancerBreast CancerNCT05080842Accutar Biotechnology Inc21
招募中
1 期
A Study of ICP-033 in Patients With Advanced Solid TumorsPatients With Advanced Solid TumorsNCT05367232Beijing InnoCare Pharma Tech Co., Ltd.60
招募中
1 期
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)Chronic Myeloid Leukemia, Chronic PhaseChronic Myeloid LeukemiaNCT06163430Terns, Inc.180